Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of Debio 0932

News   Feb 21, 2012

 
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of Debio 0932
 
 
 

RELATED ARTICLES

Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to Treatment

News

Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.

READ MORE

BC Platforms Announces Collaborations in Multiple Sclerosis Research

News

Company's technology and research platforms used to better understand genetic basis of MS.

READ MORE

Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of London

News

The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE